CO2019000787A2 - Nuevas formulaciones y composiciones de cannabis en comprimidos y métodos para su elaboración - Google Patents

Nuevas formulaciones y composiciones de cannabis en comprimidos y métodos para su elaboración

Info

Publication number
CO2019000787A2
CO2019000787A2 CONC2019/0000787A CO2019000787A CO2019000787A2 CO 2019000787 A2 CO2019000787 A2 CO 2019000787A2 CO 2019000787 A CO2019000787 A CO 2019000787A CO 2019000787 A2 CO2019000787 A2 CO 2019000787A2
Authority
CO
Colombia
Prior art keywords
compositions
methods
cannabis
elaboration
tablets
Prior art date
Application number
CONC2019/0000787A
Other languages
English (en)
Inventor
Kurt Levy
Original Assignee
Canopy Growth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61017335&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2019000787(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Canopy Growth Corp filed Critical Canopy Growth Corp
Publication of CO2019000787A2 publication Critical patent/CO2019000787A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composiciones que comprenden un aceite que tiene por lo menos un cannabinoide y por lo menos un polvo sólido y métodos para elaborar y usando las mismas. Las composiciones son apropiadas para hacer comprimidos que contienen cannabinoides prensando una composición de la presente invención con uno o más agentes de formulación, como por ejemplo aglutinantes, cargas, agentes para aumentar el volumen, excipientes, etc.
CONC2019/0000787A 2016-07-25 2019-01-28 Nuevas formulaciones y composiciones de cannabis en comprimidos y métodos para su elaboración CO2019000787A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662366517P 2016-07-25 2016-07-25
PCT/US2017/043808 WO2018022669A1 (en) 2016-07-25 2017-07-25 New cannabis tablet formulations and compositions and methods of making the same

Publications (1)

Publication Number Publication Date
CO2019000787A2 true CO2019000787A2 (es) 2019-04-30

Family

ID=61017335

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0000787A CO2019000787A2 (es) 2016-07-25 2019-01-28 Nuevas formulaciones y composiciones de cannabis en comprimidos y métodos para su elaboración

Country Status (12)

Country Link
US (3) US20190183850A1 (es)
EP (1) EP3487482A4 (es)
CN (1) CN109789095A (es)
AU (1) AU2017302559A1 (es)
BR (1) BR112019001528A8 (es)
CA (1) CA3031533A1 (es)
CL (1) CL2019000198A1 (es)
CO (1) CO2019000787A2 (es)
IL (1) IL264386B2 (es)
MX (1) MX2019001121A (es)
PE (1) PE20200478A1 (es)
WO (1) WO2018022669A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3755309A1 (en) * 2018-02-23 2020-12-30 Columbia Care LLC Hard-pressed scored splittable marijuana tablets
WO2019211772A1 (en) * 2018-05-03 2019-11-07 Radient Technologies Inc. Obtaining extracts in a solid form
WO2020092352A1 (en) * 2018-10-30 2020-05-07 Kelsie Biotech, Llc Tablets, formulations and methods for low melting point active ingredients
US20220023220A1 (en) * 2019-01-10 2022-01-27 Columbia Care Llc Rapidly disintegrating oral tablet
US10925853B2 (en) 2019-04-17 2021-02-23 Nordiccan A/S Oral cannabinoid tablet
CA3040547C (en) 2019-04-17 2021-12-07 Medcan Pharma A/S Cannabinoid lozenge formulation
US11633351B2 (en) 2019-12-13 2023-04-25 Nordiccan A/S Fast disintegrating cannabinoid tablets
EP4087547A1 (en) * 2020-01-08 2022-11-16 Société des Produits Nestlé S.A. Oral solid cannabinoid oil composition for treating gastrointestinal disorders
EP4340644A1 (en) * 2021-05-21 2024-03-27 SWM Luxembourg Process for incorporating additives into aerosol-producing substrates and products made therefrom

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991016882A1 (en) * 1990-05-08 1991-11-14 Liposome Technology, Inc. Direct spray-dried drug/lipid powder composition
JP2001507701A (ja) * 1996-12-31 2001-06-12 インヘイル・セラピューティック・システムズ・インコーポレーテッド 親水性賦形剤を有する疎水性薬剤の溶液を噴霧乾燥するための方法及びその方法によって作製された組成物
DE10296335T5 (de) * 2001-02-14 2004-04-15 G W Pharma Ltd., Salisbury Pharmazeutische Formulierungen
US6730330B2 (en) * 2001-02-14 2004-05-04 Gw Pharma Limited Pharmaceutical formulations
PA8576201A1 (es) * 2002-07-10 2004-05-26 Pfizer Prod Inc Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco
CA2664311C (en) * 2006-09-15 2015-08-18 Echo Pharmaceuticals B.V. Granulate containing a pharmaceutically active substance and method for its manufacture
CN101810593B (zh) * 2010-05-10 2012-07-18 谢恬 一种榄香烯缓释片
AU2015292915B2 (en) * 2014-07-21 2020-10-15 Pharmaceutical Productions, Inc. Solid dosage form composition for buccal or sublingual administration of cannabinoids
US20180303791A1 (en) * 2014-11-26 2018-10-25 One World Cannabis Ltd Synergistic use of cannabis for treating multiple myeloma
US10172786B2 (en) * 2014-12-16 2019-01-08 Axim Biotechnologies, Inc. Oral care composition comprising cannabinoids

Also Published As

Publication number Publication date
US20190183850A1 (en) 2019-06-20
MX2019001121A (es) 2019-10-21
BR112019001528A2 (pt) 2019-06-18
EP3487482A1 (en) 2019-05-29
EP3487482A4 (en) 2020-03-04
IL264386A (en) 2019-02-28
PE20200478A1 (es) 2020-03-03
IL264386B1 (en) 2023-04-01
IL264386B2 (en) 2023-08-01
WO2018022669A1 (en) 2018-02-01
CN109789095A (zh) 2019-05-21
CL2019000198A1 (es) 2019-05-31
CA3031533A1 (en) 2018-02-01
AU2017302559A1 (en) 2019-02-07
BR112019001528A8 (pt) 2019-07-09
US20210100771A1 (en) 2021-04-08
US20220323403A1 (en) 2022-10-13

Similar Documents

Publication Publication Date Title
CO2019000787A2 (es) Nuevas formulaciones y composiciones de cannabis en comprimidos y métodos para su elaboración
BR112017018276A2 (pt) ?composição que compreende peptidase e biotensoativo e seu uso?
CO2018006662A2 (es) Agonistas del receptor de apelina y métodos de uso
CL2018000953A1 (es) 2,4-dihidroxi-nicotinamidas como agonistas del receptor de apelina (apj)
CL2018002703A1 (es) Agentes de iarn, composiciones y métodos de uso de los mismos para tratar enfermedades asociadas con transtiretina (ttr). (divisional solicitud 201401291)
CL2018003135A1 (es) Derivados aromáticos de sulfonamida.
MX2019003735A (es) Formulaciones diluibles de cannabinoides y procesos para su preparacion.
CL2017002335A1 (es) Composiciones de cosmetica topica para combatir radicales libres
UY36705A (es) Compuestos de 4-hidroxi-3-(heteroaril)piridin-2-ona como agonistas de apj
MX2018011194A (es) 6-hidroxi-4-oxo-1,4-dihidropirimidin-5-carboxamidas como agonistas del receptor de apelina (apj).
CL2016002772A1 (es) Composiciones de insulina de rápida acción
CO2018007221A2 (es) Heteroarilhidroxipirimidinonas como agonistas del receptor de apelina (apj)
CL2019000266A1 (es) Composición de cannabis.
CL2020000632A1 (es) Composición y método para el tratamiento del autismo.
MY196308A (en) PTH Prodrugs
BR112016028476A8 (pt) compostos, composição, uso de um composto e método para o combate dos fungos nocivos
CR20170425A (es) Nuevas proteínas específicas para pioverdina y pioquelina
DOP2016000226A (es) Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
CO2018005753A2 (es) Composición hemostática
CL2019001249A1 (es) Composiciones de recubrimiento y métodos de uso de las mismas.
MX2016014509A (es) Formulacion de vitamina soluble en grasa.
CL2016000038A1 (es) Piraxolo-piridinaminas sustituidas
ECSP22012650A (es) Composiciones que comprenden tigolaner para el control de parásitos
CL2023000892A1 (es) Composiciones terapéuticas y métodos para el tratamiento de la hepatitis b (divisional).
BR112018077510A2 (pt) variantes de lipase e composições que compreendem tensoativo e variante de lipase